Appili Therapeutics (OTCMKTS:APLIF) versus Ascendis Pharma A/S (NASDAQ:ASND) Head-To-Head Comparison

Appili Therapeutics (OTCMKTS:APLIF) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Appili Therapeutics and Ascendis Pharma A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Appili Therapeutics	0	0	0	0	0.00
Ascendis Pharma A/S	1	0	16	2	3.00

Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 40.36%. Given Ascendis Pharma A/S’s stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Appili Therapeutics.

Profitability

This table compares Appili Therapeutics and Ascendis Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Appili Therapeutics	N/A	N/A	-190.26%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Risk & Volatility

Appili Therapeutics has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500.

Earnings & Valuation

This table compares Appili Therapeutics and Ascendis Pharma A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Appili Therapeutics	$70,000.00	22.43	-$1.89 million	($0.03)	-0.40
Ascendis Pharma A/S	$865.78 million	15.16	-$258.00 million	$8.67	24.27

Appili Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Appili Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Ascendis Pharma A/S beats Appili Therapeutics on 10 of the 12 factors compared between the two stocks.

About Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.